Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eslicarbazepine Acetate as Add-on for Partial-onset Seizures
NCT03116828Phase 4Completed
- Sponsor
- Sumitomo Pharma America
- Start
- Jul 2017
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 4, open-label trial of eslicarbazepine acetate in focal onset seizure (2 arms), sponsored by Sumitomo Pharma America. Primary endpoint: The Number of Subjects Completing 24 Weeks Adjunctive Therapy During Maintenance Phase. Started Jul 2017; status: completed.
02
Drugs
eslicarbazepine acetate
03
Conditions
focal onset seizure
Beyond the preview
Go deeper on NCT03116828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03116828.